Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
1,759
Views
1
CrossRef citations to date
0
Altmetric
Influenza – Short Report

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice

Abenaya Muralidharana Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada;b Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USAView further author information
,
Caroline Gravelc Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, CanadaView further author information
,
Greg Harrisd Human Health Therapeutics (HHT) Research Center, National Research Council of Canada, Ottawa, CanadaView further author information
,
Anwar M. Hasheme Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia;f Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi ArabiaView further author information
,
Wanyue Zhanga Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada;c Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, CanadaView further author information
,
David Safronetzg National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, CanadaView further author information
,
Gary Van Domselaarg National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, CanadaView further author information
,
Florian Krammerb Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USAORCID Iconhttps://orcid.org/0000-0003-4121-776XView further author information
ORCID Icon,
Simon Sauvec Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, CanadaView further author information
,
Michael Rosu-Mylesa Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada;c Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, CanadaView further author information
,
Lisheng Wanga Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, CanadaView further author information
,
Wangxue Chend Human Health Therapeutics (HHT) Research Center, National Research Council of Canada, Ottawa, CanadaORCID Iconhttps://orcid.org/0000-0003-0958-7728View further author information
ORCID Icon &
Xuguang Lia Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada;c Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, CanadaCorrespondence[email protected]
View further author information
 show all
Article: 2083428 | Received 07 Mar 2022, Accepted 25 May 2022, Published online: 20 Jun 2022

References

  • World Health Organization. Influenza update - 331. Geneva (Switzerland): WHO; 2018.
  • Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26:1. [accessed 2021 Jun 25]. /pmc/articles/PMC3074182/.
  • Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, Wang D, Nelson EA, Li F, Palese P. Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the orthomyxoviridae family. Mbio. 2014;5(2). [accessed 2021 Jun 25]. /pmc/articles/PMC3958797/.
  • Hause BM, Ducatez M, Collin EA, Ran Z, Liu R, Sheng Z, Armien A, Kaplan B, Chakravarty S, Hoppe AD, et al. Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses. PLoS Pathog. 2013;9(2):e1003176. [accessed 2021 Jun 25]. /pmc/articles/PMC3567177/.
  • Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother. 1999;44(suppl_2):3–8. [accessed 2021 Jul 17]. doi:10.1093/jac/44.suppl_2.3.
  • Capua I, Alexander DJ. Human health implications of avian influenza viruses and paramyxoviruses. Eur J Clin Microbiol Infect Dis. 2003;23(1):1–6. [accessed 2022 Feb 21]. doi:10.1007/s10096-003-1059-3.
  • Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, et al. New world bats harbor diverse influenza a viruses. PLoS Pathog. 2013;9(10):e1003657. [accessed 2021 Jun 25]. /pmc/articles/PMC3794996/.
  • Gao R, Sheng Z, Sreenivasan CC, Wang D, Li F. Influenza a virus antibodies with antibody-dependent cellular cytotoxicity function. Viruses. 2020;12. [accessed 2021 Jun 25]. /pmc/articles/PMC7150983/.
  • Russell RJ, Kerry PS, Stevens DJ, Steinhauer DA, Martin SR, Gamblin SJ, Skehel JJ. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S a. 2008;105(46):17736–17741. [accessed 2022 Feb 21]. doi:10.1073/pnas.0807142105.
  • Koutsakos M, Nguyen TH, Barclay WS, Kedzierska K. Knowns and unknowns of influenza B viruses. Future Microbiol. 2016;11(1):119–135. [accessed 2021 Jun 25]. doi:10.2217/fmb.15.120.
  • Jennings L, Huang QS, Barr I, Lee PI, Kim WJ, Buchy P, Sanicas M, Mungall BA, Chen J Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region. Influenza Other Respi Viruses. 2021;12(3):383–411. [accessed 2018 Jun 25]]. https://pubmed.ncbi.nlm.nih.gov/29127742/.
  • De Sandt CE V, Bodewes R, Rimmelzwaan GF, De Vries RD. Influenza B viruses: not to be discounted. Future Microbiol. 2015;10:1447–1465. [accessed 2021 Jun 25]. https://pubmed.ncbi.nlm.nih.gov/26357957/.
  • Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175(1):59–68. [accessed 2021 Jun 25]. doi:10.1016/0042-6822(90)90186-U.
  • Boivin S, Cusack S, Ruigrok RWH, Hart DJ. Influenza a virus polymerase: structural insights into replication and host adaptation mechanisms. J Biol Chem. 2010;285:28411–28417. [accessed 2021 Jun 25]. /pmc/articles/PMC2937865/.
  • Air GM. Influenza virus antigenicity and broadly neutralizing epitopes. Curr Opin Virol. 2015;11:113–121. [accessed 2021 Jun 25]. /pmc/articles/PMC4456283/.
  • Huang KYA, Rijal P, Schimanski L, Powell TJ, Lin TY, McCauley JW, Daniels RS, Townsend AR. Focused antibody response to influenza linked to antigenic drift. J Clin Invest. 2015;125(7):2631–2645. [accessed 2021 Jun 25]. /pmc/articles/PMC4613558/.
  • Schmidt AG, Do KT, McCarthy KR, Kepler TB, Liao HX, Moody MA, Haynes BF, Harrison SC. Immunogenic stimulus for germline precursors of antibodies that engage the influenza hemagglutinin receptor-binding site. Cell Rep. 2015;13(12):2842–2850. [accessed 2021 Jun 25]. /pmc/articles/PMC4698027/.
  • Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza a viruses. Microbiol Rev. 1992;56(1):152–179. [accessed 2022 Feb 21]. doi:10.1128/mr.56.1.152-179.1992.
  • Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, et al. Characterization of an avian influenza a (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 1998;279(5349):393–396. [accessed 2022 Feb 21]. doi:10.1126/science.279.5349.393.
  • Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, et al. Avian-To-Human transmission of H9N2 subtype influenza a viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A. 2000;97(17):9654–9658. [accessed 2022 Feb 21]. doi:10.1073/pnas.160270697.
  • Fouchier RAM, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SAG, Munstert V, Kuikent T, Rimmelzwaan GF, Schutten M, Van Doornum GJJ, et al. Avian influenza a virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101(5):1356–1361. [accessed 2022 Feb 21]. doi:10.1073/pnas.0308352100.
  • Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12(1):9–14. [accessed 2021 Jun 25]. /pmc/articles/PMC3291411/.
  • Von Holle TA, Anthony Moody M. Influenza and antibody-dependent cellular cytotoxicity. Front Immunol. 2019;10:1457. [accessed 2021 Jun 25]. /pmc/articles/PMC6611398/.
  • Fowlkes AL, Arguin P, Biggerstaff MS, Gindler J, Blau D, Jain S, Dhara R, McLaughlin J, Turnipseed E, Meyer JJ, et al. Epidemiology of 2009 pandemic influenza a (H1N1) deaths in the United States, April-July 2009. Clin Infect Dis. 2011;52(Supplement 1):S60–S68. [accessed 2021 Jun 25]. doi:10.1093/cid/ciq022.
  • M Hashem A, M Doyle T, Van Domselaar G, Farnsworth A, Li C, Wang J, He R, Li X. Recent developments in bioinformatics analyses of influenza a virus surface glycoproteins and their biological relevance. Curr Bioinform. 2011;6(4):415–426. doi:10.2174/157489311798073007.
  • Chun S, Li C, Van Domselaar G, Wang J, Farnsworth A, Cui X, Rode H, Cyr TD, He R, Li X. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza a viral hemagglutinins. Vaccine. 2008;26(48):6068–6076. doi:10.1016/j.vaccine.2008.09.015.
  • Gravel C, Muralidharan A, Duran A, Zetner A, Pfeifle A, Zhang W, Hashem A, Tamming L, Farnsworth A, Loemba H, et al. Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. iScience. 2021;24(11):103328. [accessed 2022 Feb 21]. doi:10.1016/j.isci.2021.103328.
  • Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin Infect Dis. 2014;59(11):1519–1524. [accessed 2021 Jun 25]. doi:10.1093/cid/ciu664.
  • Tafalla M, Buijssen M, Geets R, Vonk Noordegraaf-Schouten M. A comprehensive review of the epidemiology and disease burden of influenza B in 9 European countries. Hum Vaccines Immunother. 2021;12(4):993–1002.[accessed 2016 Jun 25]. doi:10.1080/21645515.2015.1111494.
  • Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, Dunand CJH, Taylor WM, Lim S, Huang M, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med. 2015;7(316):316ra192. [accessed 2021 Jun 25]. /pmc/articles/PMC4770855/.
  • Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013;3(5):521–530. [accessed 2021 Jun 25]. /pmc/articles/PMC3804342/.
  • Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses. Nat Struct Mol Biol. 2009;16(3):265–273. [accessed 2021 Jun 25]. https://www.nature.com/articles/nsmb.1566.
  • Ekiert DC, Bhabha G, Elsliger MA, Friesen RHE, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246–251. [accessed 2021 Jun 25]. doi:10.1126/science.1171491.
  • Hashem AM Prospects of HA-based universal influenza vaccine. Biomed Res Int. 2015. [accessed 2022 Feb 21]. https://pubmed.ncbi.nlm.nih.gov/25785268/.
  • Hashem AM, Van Domselaar G, Li C, Wang J, She YM, Cyr TD, Sui J, He R, Marasco WA, Li Xuguang X. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza a virus. Biochem Biophys Res Commun. 2010;403(2):247–251. [accessed 2021 Jun 25]. doi:10.1016/j.bbrc.2010.11.030.
  • Li C, Jaentschke B, Song Y, Wang J, Cyr TD, Van Domselaar G, He R, Li X. A simple slot blot for the detection of virtually all subtypes of the influenza a viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc. 2010;5(1):14–19. [accessed 2021 Jun 25]. doi:10.1038/nprot.2009.200.
  • Dilillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143–151. [accessed 2022 Feb 21]. doi:10.1038/nm.3443.
  • Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ Antibody-Dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. 2013 [accessed 2022 Feb 21]. http://jvi.asm.org/.
  • Dunand CJH, Leon PE, Huang M, Palese P, Krammer F, Wilson PC. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. 2016. [accessed 2022 Feb 21]. doi:10.1016/j.chom.2016.05.014.
  • Jegaskanda S, Laurie KL, Amarasena TH, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks AG, Reading PC, Kent SJ. Age-Associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza a virus subtype H1N1. 2013;208(7):1051–1061. [accessed 2022 Feb 21]. https://academic.oup.com/jid/article-abstract/208/7/1051/2192734.
  • Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de RR, Winnall WR, Stratov I, Brooks AG, Reading PC, et al. Cross-Reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol. 2013;190(4):1837–1848. [accessed 2022 Mar 3]. https://www.jimmunol.org/content/190/4/1837.
  • DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016;126(2):605–610. [accessed 2022 Feb 21]. doi:10.1172/JCI84428.
  • Wu NC, Xie J, Zheng T, Nycholat CM, Grande G, Paulson JC, Lerner RA, Wilson IA. Diversity of functionally permissive sequences in the receptor-binding site of influenza hemagglutinin. Cell Host Microbe. 2017;21(6):742–753.e8. [accessed 2022 Feb 23]. doi:10.1016/j.chom.2017.05.011.
  • Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza a virus infection in mice. Vaccine. 2003;21(23):3212–3218. doi:10.1016/S0264-410X(03)00234-2.
  • Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol. 2007;18(6):529–536. [accessed 2021 Jun 25]. doi:10.1016/j.copbio.2007.11.002.
  • Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis. 2006;12(4):569–574. [accessed 2021 Jun 25]. doi:10.3201/eid1204.051020.
  • Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ. Protection against multiple influenza a subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005;23(46–47):5404–5410. [accessed 2021 Jun 25]. doi:10.1016/j.vaccine.2005.04.047.
  • Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland family study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis. 2006;193(1):49–53. [accessed 2021 Jun 25]. doi:10.1086/498980.
  • Sánchez-Fauquier A, Villanueva N, Melero JA. Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits. Arch Virol. 1987;97(3–4):251–265. [accessed 2021 Jun 25]. https://link.springer.com/article/10.1007/BF01314425.
  • Tkáčová M, Varečková E, Baker IC, Love JM, Ziegler T. Evaluation of monoclonal antibodies for subtyping of currently circulating human type a influenza viruses. J Clin Microbiol. 1997;35(5):1196–1198. [accessed 2021 Jun 25]. /pmc/articles/PMC232728/?report=abstract.
  • Sanchez-Fauquier A, Guillen M, Martin J, Kendal AP, Melero JA. Conservation of epitopes recognized by monoclonal antibodies against the separated subunits of influenza hemagglutinin among type a viruses of the same and different subtypes. Arch Virol. 1991;116(1–4):285–292. [accessed 2021 Jun 25]. doi:10.1007/BF01319250.
  • Russ G, Polakova K, Kostolansky F, Styk B, Vancikova M. Monoclonal antibodies to glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. Acta Virol. 1987;31:374–386.
  • Guthmiller JJ, Han J, Li L, Freyn AW, Liu STH, Stovicek O, Stamper CT, Dugan HL, Tepora ME, Utset HA, et al. First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Sci Transl Med. 2021;13(596). [accessed 2022 Feb 21]. doi:10.1126/scitranslmed.abg4535.
  • Guthmiller JJ, Han J, Utset HA, Li L, Lan LYL, Henry C, Stamper CT, McMahon M, O’-Dell G, Fernández-Quintero ML, et al. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature. 2022;602(7896):314–320. [accessed 2022 Feb 21]. doi:10.1038/s41586-021-04356-8.
  • Corti D, Suguitan AL, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010;120(5):1663–1673. [accessed 2022 Feb 21]. doi:10.1172/JCI41902.
  • Ekiert DC, Friesen RHE, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJWM, Brandenburg B, et al. A highly conserved neutralizing epitope on group 2 influenza a viruses. Science. 2011;333(6044):843–850. [accessed 2022 Feb 21]. doi:10.1126/science.1204839.
  • Friesen RHE, Lee PS, Stoop EJM, Hoffman RMB, Ekiert DC, Bhabha G, Yu W, Juraszek J, Koudstaal W, Jongeneelen M, et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S a. 2014;111(1):445–450. [accessed 2022 Feb 21]. doi:10.1073/pnas.1319058110.
  • Bliss CM, Freyn AW, Caniels TG, Leyva-Grado VH, Nachbagauer R, Sun W, Tan GS, Gillespie VL, McMahon M, Krammer F, et al. A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Mol Ther. 2022 [accessed 2022 Feb 21]. https://pubmed.ncbi.nlm.nih.gov/34999208/
  • Kirkpatrick E, Qiu X, Wilson PC, Bahl J, Krammer F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci Rep. 2018;8(1). [accessed 2022 Feb 21]. doi:10.1038/s41598-018-28706-1.
  • Roubidoux EK, Carreño JM, McMahon M, Jiang K, van Bakel H, Wilson P, Krammer F, Schultz-Cherry S. Mutations in the hemagglutinin stalk domain do not permit escape from a protective, stalk-based vaccine-induced immune response in the mouse model. Mbio. 2021;12(1):1–14. [accessed 2022 Feb 21]. doi:10.1128/mBio.03617-20.
  • Krammer F. The human antibody response to influenza a virus infection and vaccination. Nat Rev Immunol. 2019;19(6):383–397. [accessed 2022 Feb 21]. doi:10.1038/s41577-019-0143-6.
  • Tan J, Asthagiri Arunkumar G, Krammer F. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? Curr Opin Immunol. 2018;53:45–50. [accessed 2022 Feb 21]. https://pubmed.ncbi.nlm.nih.gov/29677684/.
  • Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect. 2017;23(4):222–228. [accessed 2022 Feb 21]. doi:10.1016/j.cmi.2017.02.009.
  • Van Baalen CA, Els C, Sprong L, Van Beek R, Van Der Vries E, Adme O, Rimmelzwaan GF, McAdam AJ. Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. J Clin Microbiol. 2014;52(5):1672–1677. [accessed 2022 Feb 21]. doi:10.1128/JCM.03575-13.
  • Thyagarajan B, Bloom JD. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. Elifesciences Org Thyagarajan Bloom eLife. 2014;3:3300.
  • Wu NC, Thompson AJ, Lee JM, Su W, Arlian BM, Xie J, Lerner RA, Yen HL, Bloom JD, Wilson IA. Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Science. 2020;368(6497):1335–1340. [accessed 2022 Feb 23]. doi:10.1126/science.aaz5143.
  • Asaoka N, Tanaka Y, Sakai T, Fujii Y, Ohuchi R, Ohuchi M. Low growth ability of recent influenza clinical isolates in MDCK cells is due to their low receptor binding affinities. Microbes Infect. 2006;8(2):511–519. [accessed 2022 Feb 23]. doi:10.1016/j.micinf.2005.08.006.
  • Dolskiy AA, Grishchenko IV, Yudkin DV. Cell cultures for virology: usability, advantages, and prospects. Int J Mol Sci. 2020;21(21):1–23. [accessed 2022 Feb 21]. doi:10.3390/ijms21217978.
  • Lombardo T, Dotti S, Renzi S, Ferrari M. Susceptibility of different cell lines to avian and swine influenza viruses. J Virol Methods. 2012;185(1):82–88. [accessed 2022 Feb 21]. doi:10.1016/j.jviromet.2012.06.008.
  • Ilyushina NA, Ikizler MR, Kawaoka Y, Rudenko LG, Treanor JJ, Subbarao K, Wright PF. Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium. J Virol. 2012;86(21):11725. [accessed 2022 Feb 21]. /pmc/articles/PMC3486302/.
  • Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, Kurosawa Y, Wilson IA Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun. 2014;5. [accessed 2022 Feb 21]. https://pubmed.ncbi.nlm.nih.gov/24717798/.
  • Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337:1343–1348. [accessed 2021 Jul 17]. https://www.science.org/doi/abs/10.1126/science.1222908.
  • Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins. Science. 2011;333(6044):850–856. [accessed 2022 Feb 21]. doi:10.1126/science.1205669.
  • Doud MB, Hensley SE, Bloom JD, Lauring AS. Complete mapping of viral escape from neutralizing antibodies. PLoS Pathog. 2017;13(3):e1006271. [accessed 2022 Feb 23]. doi:10.1371/journal.ppat.1006271.
  • Jennewein MF, Mabuka J, Papia CL, Boudreau CM, Dong KL, Ackerman ME, Ndung’-U T, Alter G Tracking the trajectory of functional humoral immune responses following acute HIV infection. Front Immunol. 2020;11. [accessed 2022 Mar 5]. https://pubmed.ncbi.nlm.nih.gov/32849622/.
  • Boudreau CM, Burke JS, Shuey KD, Wolf C, Katz J, Tielsch J, Khatry S, LeClerq SC, Englund JA, Chu HY, et al. Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial. Cell Rep. 2022;38(6):110337. [accessed 2022 Mar 5]. doi:10.1016/j.celrep.2022.110337.
  • Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, et al. Modified vaccinia virus ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol. 2014;88:13418–13428. [accessed 2021 Jun 25]. /pmc/articles/PMC4249095/.
  • Vanderven HA, Liu L, Ana-Sosa-Batiz F, Nguyen THO, Wan Y, Wines B, Mark Hogarth P, Tilmanis D, Reynaldi A, Parsons MS, et al. Fc functional antibodies in humans with severe H7N9 and seasonal influenza. J Clin Invest. 2017;2. [accessed 2021 Jun 25]. /pmc/articles/PMC5499372/.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.